DarioHealth (Formerly Known As LabStyle Innovations)
About DarioHealth (Formerly Known As LabStyle Innovations)
DarioHealth Corp. (NASDAQ: DRIO) creates innovative mobile and digital tools that empower and engage users to lead healthier lives. DarioHealth’s “Real time. Real data. Real people” approach and strategy is positioning the company as a major player in the mHealth industry; an industry currently worth $10B and expected to reach $31B by 2020*. DarioHealth’s flagship product, the Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app (iOS & Android), website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.The Dario Smart Diabetes Management Solution was granted U.S. FDA marketing clearance in December 2015 and is set to launch in the current quarter in the U.S. – the largest market in the world for glucose monitoring. LabStyle has been granted patents, and is pursuing additional applications - in multiple areas covering the specific processes related to blood glucose level measurement, as well as more general methods for rapid body fluids testing using mobile devices and cloud-based services. Dario™ is currently available in the UK, New Zealand, Netherlands, Australia, Israel, Canada, Belgium and Italy. Dario received reimbursement coverage in the UK, Australia, Israel, Italy and Canada. Sequential quarterly revenues are growing rapidly, reflecting strong market adoption.
LEADERSHIP:
CEO: Erez Raphael
CFO: Zvi Ben-David
214 articles about DarioHealth (Formerly Known As LabStyle Innovations)
-
DarioHealth CEO Erez Raphael Presents to Digital Therapeutics Leaders at DTx East 2019
9/23/2019
DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael, DarioHealth's Chief Executive Officer, will be a speaker at the second annual DTx East 2019 conference taking place at Harvard Medical School in Boston, MA from September 24-26, 2019.
-
Dance Biopharm Partners With DarioHealth to Expand Access to Digital Therapeutics Platform for Patients With Chronic Diseases
9/11/2019
Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario" (Nasdaq: DRIO), a leading, global digital therapeutics company, to expand access to a personalized digital health management platform for patients with chronic diseases.
-
DarioHealth to Present at RHK Capital Disruptive Growth Conference on Thursday, September 5th
8/28/2019
Leading global digital therapeutics company DarioHealth Corp. (Nasdaq: DRIO) today announced that DarioHealth's Chief Executive Officer, Erez Raphael, will present to and meet with investors and analysts attending the RHK Capital Disruptive Growth Conference on Thursday, September 5, 2019 in New York City.
-
DarioHealth Reports Results For Second Quarter 2019
8/13/2019
Global digital therapeutics innovator DarioHealth Corp., reported financial and operational results for the second quarter ended June 30, 2019.
-
DarioHealth® Clinical Study Data Shows the Dario Membership Program Assists Diabetes Patients in Achieving Pre-Diabetic Blood-Glucose Levels and Consistent In-Range Measurements
8/12/2019
Dario Membership users with diabetes achieved a 39% increase of in-range, blood-glucose measurements
-
DarioHealth to Host Second Quarter 2019 Conference Call August 13, 2019
8/7/2019
Earnings Discussion and Business Update Scheduled for 9:00 am EDT
-
DarioHealth to Present New Data at AADE Conference That Shows Improvement of Type 2 Diabetes Blood-glucose Levels Using MyDario™ App
8/6/2019
DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company and member of the Digital Therapeutics Alliance (DTx), today announced its plan to present the results of a new Dario app user study at the upcoming annual conference of the American Association of Diabetes Educators (AADE) in Houston, Texas on August 9-12, 2019.
-
DarioHealth Launches New Blood Pressure Monitoring System
7/30/2019
New offering enables users to integrate blood pressure readings into the Dario mobile app to gain better understanding and control of overall health.
-
DarioHealth Granted 180-day Extension by Nasdaq to Regain Compliance With bid Price Rule
7/8/2019
On July 5, 2019, it received notification from Nasdaq that the Company has been granted an additional 180-day compliance period, or until December 23, 2019, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2)
-
DarioHealth Reports Improvement in Glycemic Outcomes With Key Diabetes Findings at the American Diabetes Association's 79th Scientific Sessions
6/11/2019
Digital Therapeutics leader DarioHealth caps off successful week at the ADA with Two Studies Presenting New Real-World Data in the Field of Diabetes
-
DarioHealth Signs New Functional Medicine Clinic to Its Digital Diabetes Platform
6/4/2019
Functional Medicine Center of Fort Collins, in Fort Collins, CO will incorporate Dario's digital diabetes platform to its health and wellness improvement programs
-
DarioHealth to Present New Evidence of Digital Therapeutics Benefits at 2019 American Diabetes Association Conference
5/29/2019
Outcomes of several new studies to be released, demonstrating improved life with diabetes.
-
DarioHealth Corp. Announces Pricing of $7.2 Million Public Offering of Common Stock
5/22/2019
DarioHealth Corp. announced the pricing of an underwritten public offering of 4,855,341 shares of common stock at a price to the public of $0.60 per share and pre-funded warrants to purchase 7,175,525 shares of common stock at a price to the public of $0.5999 per pre-funded warrant for aggregate gross proceeds of approximately $7,200,000, before underwriting discounts and offering expenses.
-
DarioHealth Reports Record Results For First Quarter 2019
5/13/2019
Global digital therapeutics innovator DarioHealth Corp. reported record financial and operational results for the first quarter ended March 31, 2019.
-
DarioHealth to Host First Quarter 2019 Conference Call May 13, 2019
5/7/2019
Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its first quarter 2019 results on Monday, May 13, and host a conference call the same morning at 9:00 am EDT.
-
DarioHealth Announces New Partnership With the American Diabetes Association
5/3/2019
DarioHealth's mission is to support people with diabetes and other chronic conditions in the U.S. and around the world.
-
Dario® Elevates Digital Therapeutics Capabilities by Further Enhancing Patient Experience
4/10/2019
New version V4.2.0 is a testament to Dario's relentless commitment to patients with chronic conditions.
-
DarioHealth Signs Leading Functional Medicine Clinic to DarioEngage™ Remote Digital Diabetes Platform
4/1/2019
The 'Per Engaged Member Per Month' (PEMPM) model is value-driven, simple and effective to cover the needs of providers and their patients
-
DarioHealth Granted License by Health Canada to Sell Dario Smart Glucose Meters for Lightning® Connector Enabled iPhones
3/20/2019
Significant expansion of Dario's Canadian market opportunity to include iPhone 7, 8, and iPhone X user
-
DarioHealth to Host Fourth Quarter and Year End 2018 Conference Call March 25, 2019
3/18/2019
Earnings Discussion and Business Update Scheduled for 9:00 am EDT